Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

Alan Bryce interviews Tanya Dorff about recommendations from the 2024 US Prostate Cancer Consensus Conference addressing clinical gray areas in prostate cancer management.

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

pasritamig, KLK2 T-cell engager, bispecific antibody prostate cancer, Phase I trial results, mCRPC immunotherapy, Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study with Capucine ...

Alan Bryce hosts Mary-Ellen Taplin to discuss key recommendations from the 2024 US Prostate Cancer Consensus Conference addressing biochemical recurrence management. Dr. Taplin emphasizes that PSMA ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

UroToday's exclusive Video Lecture content covering mCRPC Treatment.

PSMA and Beyond 2025 CAR-T and Bispecific antibodies targeting PSMA, Poseida trial, neuroendocrine prostate cancer, STEAP-1.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025 held in Washington, D.C., United States, between July 30 th and August 1 st. was host to the Session: Lessons ...